Request Sample Inquiry
Orphan Drugs Market

Orphan Drugs Market

Orphan Drugs Market Global Industry Assessment & Forecast

img
Healthcare
# Pages:

169

Base Year:

2021

Nov - 2021

Format:

Report Code:

VMR-2021-0236

Segments Covered
  • By Disease Type Oncologic Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, Other Rare Diseases
  • By Indication Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma, Others
Snapshot
Forecast YearsForecast Years: 2021 - 2028
Historical YearsHistorical Years: 2016 - 2020
Revenue 2021Revenue 2021: 112.36 Billion
Revenue 2028Revenue 2028: 3199.3 Billion
Revenue CAGRRevenue CAGR (2021 - 2028): 7.4
Fastest Growing Region Fastest Growing Region (2022 - 2028) North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report
  • Go To Market Strategy
  • Region Specific Market Dynamics
  • Region Level Market Share
  • Import Export Analysis
  • Production Analysis
  • Others Request Customization Speak To Analyst

Table of Content:

  1. Chapter No. 1: Introduction
    1. Report Scope
    2. Objectives of the Study
    3. USP & Key Offerings
    4. Target Audience
    5. Vantage Market Research Report Guidance/Walk-through
  2. Chapter No. 2: Premium Insights
    1. Market Snapshot
    2. Top Investment Pockets
      1. Market Attractiveness Analysis, By Disease Type
      2. Market Attractiveness Analysis, By Indication
      3. Market Attractiveness Analysis, By North America
    3. Insights from Primary Respondents
  3. Chapter No. 3: Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter’s Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
    10. Pricing Analysis
    11. Patent Analysis
    12. Value Chain Analysis
    13. Downstream Buyers
    14. Distributors/Traders List
  4. Chapter No. 4: Competitive Landscape
    1. Competition Matrix – 2020
    2. Company Market Share Analysis – 2020
      1. Company Market Share, 2020
      2. Company Market Revenue, 2017 – 2020 (USD Million)
      3. Company Y-o-Y Growth, 2018 – 2020 (%)
    3. Strategic Developments
      1. CAcquisitions & Mergers
      2. New Product Launch
      3. New Product Launch
    4. New Product Launch
  5. Chapter No. 5: COVID 19 Impact Analysis
    1. Impact Assessment of COVID-19 Pandemic, By North America
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    2. Quarterly Market Revenue Forecast by North America 2020 & 2021
    3. Pre COVID-19 Market Revenue, By North America, 2016-2019 (USD Million)
    4. Post COVID-19 Market Revenue, By North America, 2020-2028 (USD Million)
    5. Key Strategies Undertaken by Companies to Tackle COVID-19
    6. Short Term Dynamics
    7. Long Term Dynamics
  6. Chapter No. 6: Global Orphan Drugs Market - Segment Analysis
    1. Overview
    2. Global Orphan Drugs Market, 2016 – 2028 (USD Million)
      1. Global Market Revenue, By North America, 2020 & 2028
    3. Global Market Revenue, By North America, 2020 & 2028
      1. Global Market Revenue, By North America, 2020 & 2028
    4. Global Keyword Market - By Indication
      1. Overview
    5. Global Keyword Market - By North America
      1. Overview
      2. Global Market Revenue, By North America, 2016 – 2028 (USD Million)
  7. Chapter No. 7: North America Orphan Drugs Market - Segment Analysis
    1. Overview
    2. North America Orphan Drugs Market, 2016 – 2028 (USD Million)
    3. North America Market, By Disease Type
      1. North America Market Revenue, By Disease Type, 2016 – 2028
    4. North America Market, By Indication
      1. North America Market Revenue, By Indication, 2016 – 2028
    5. North America Market, By
      1. North America Market Revenue, By , 2016 – 2028 (USD Million)
  8. Chapter No. 8: Europe Orphan Drugs Market - Segment Analysis
    1. Overview
    2. Europe Orphan Drugs Market, 2016 – 2028 (USD Million)
      1. Europe Market Revenue Share, By , 2020 & 2028
    3. Europe Market, By Disease Type
      1. Europe Market Revenue, By Disease Type, 2016 – 2028
    4. Europe Market, By Indication
      1. Europe Market Revenue, By Indication, 2016 – 2028
    5. Europe Market, By
      1. Europe Market Revenue, By , 2016 – 2028 (USD Million)
  9. Chapter No. 9: Asia Pacific Orphan Drugs Market - Segment Analysis
    1. Overview
    2. Asia Pacific Orphan Drugs Market, 2016 – 2028 (USD Million)
      1. Asia Pacific Market Revenue Share, By , 2020 & 2028
    3. Asia Pacific Market, By Disease Type
      1. Asia Pacific Market Revenue, By Disease Type, 2016 – 2028
    4. Asia Pacific Market, By Indication
      1. Asia Pacific Market Revenue, By Indication, 2016 – 2028
    5. Asia Pacific Market, By
      1. Asia Pacific Market Revenue, By , 2016 – 2028 (USD Million)
  10. Chapter No. 10: Latin America Orphan Drugs Market - Segment Analysis
    1. Overview
    2. Latin America Orphan Drugs Market, 2016 – 2028 (USD Million)
      1. Latin America Market Revenue Share, By , 2020 & 2028
    3. Latin America Market, By Disease Type
      1. Latin America Market Revenue, By Disease Type, 2016 – 2028
    4. Latin America Market, By Indication
      1. Latin America Market Revenue, By Indication, 2016 – 2028
    5. Latin America Market, By
      1. Latin America Market Revenue, By , 2016 – 2028 (USD Million)
  11. Chapter No. 11: Middle East & Africa Orphan Drugs Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Orphan Drugs Market, 2016 – 2028 (USD Million)
      1. Middle East & Africa Market Revenue Share, By , 2020 & 2028
    3. Middle East & Africa Market, By Disease Type
      1. Middle East & Africa Market Revenue, By Disease Type, 2016 – 2028
    4. Middle East & Africa Market, By Indication
      1. Middle East & Africa Market Revenue, By Indication, 2016 – 2028
    5. Middle East & Africa Market, By
      1. Middle East & Africa Market Revenue, By , 2016 – 2028 (USD Million)
  12. Chapter No. 12: Marketing Strategy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
    5. Economic/Political Environmental Change
  13. Chapter No. 13: Company Profiles
    1. Company
  14. Chapter No. 14: Research Methodology
    1. Research Methodology
    2. Phase I - Secondary Research
    3. Phase II - Data Modeling
      1. Company Share Analysis Model
      2. Revenue Based Modeling
    4. Phase III - Primary Research
    5. Research Limitations
      1. Research Limitations
FAQ
Frequently Asked Question

  • The global Orphan Drugs valued at 112.36 Billion in 2020 and is expected to reach 3199.3 Billion in 2028 growing at a CAGR of 7.4%.

  • The prominent players in the market are RegeneRX Biopharmaceuticals Inc., F.Hoffman-La Roche AG, Pfizer Inc., Shire PLC, AbbVie Inc., Alexion, Bayer, Celgene Corporation, Johnson & Johnson Services Inc., Sanofi, Novartis AG, Merck & Co. Inc., Amryt Pharma PLC, Brisol-Myers Squibb Company..

  • The market is project to grow at a CAGR of 7.4% between 2021 and 2028.

  • The driving factors of the Orphan Drugs include

    • Demand has increased substantial for the orphan drugs due to surge in occurrence of rare diseases. Furthermore, the increase in awareness with respect to rare diseases among the populace, rise in investment in R&D, and drug development is fueling the market growth.
    • Rising healthcare spending nd improving healthcare infrastrcture is another driving factor for the market.

  • North America was the leading regional segment of the Orphan Drugs in 2020.

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy